# Synergistic Anticancer Activity of Annona muricata Leaf Extract and Cisplatin in 4T1 Triple-Negative Breast Cancer Cells

**Authors:** Oumayma Kouki, Mohamed Montassar Lasram, Amel Abidi, Jérôme Leprince, Imen Ghzaiel, John J. Mackrill, Taoufik Ghrairi, Gérard Lizard, Olfa Masmoudi-Kouki

PMC · DOI: 10.3390/cells15030213 · 2026-01-23

## TL;DR

Annona muricata leaf extract shows anti-cancer effects in breast cancer cells and enhances the effectiveness of cisplatin by reducing inflammation and shifting cell death mechanisms.

## Contribution

The study demonstrates a novel synergistic effect of Annona muricata leaf extract with cisplatin in breast cancer treatment.

## Key findings

- Annona muricata leaf extract induces autophagy-mediated cell death in 4T1 breast cancer cells.
- Combined treatment with cisplatin and the extract enhances anti-cancer efficacy by shifting cell death from apoptosis to autophagy.
- The extract reduces cisplatin-induced inflammation by inhibiting TNFα and IL-6 gene expression.

## Abstract

What are the main findings?
Annona muricata leaf extract exhibits significant anti-tumor activity in 4T1 breast cancer cells.Annona muricata leaf induces autophagy-mediated cell death via mTOR downregulation and increased Beclin1 and LC3 expression

Annona muricata leaf extract exhibits significant anti-tumor activity in 4T1 breast cancer cells.

Annona muricata leaf induces autophagy-mediated cell death via mTOR downregulation and increased Beclin1 and LC3 expression

What are the implications of the main finding?
Combined treatment with cisplatin shifts cell death from intrinsic apoptosis to autophagy, enhancing anti-cancer efficacy.Annona muricata leaf extract reduces cisplatin-induced inflammation by inhibiting TNFα expression and promoting IL-10 expression.

Combined treatment with cisplatin shifts cell death from intrinsic apoptosis to autophagy, enhancing anti-cancer efficacy.

Annona muricata leaf extract reduces cisplatin-induced inflammation by inhibiting TNFα expression and promoting IL-10 expression.

Breast cancer remains one of the leading causes of cancer-related mortality among women worldwide. Although cisplatin is widely used in chemotherapy, its clinical efficacy is often limited by adverse effects and resistance. Thus, natural bioactive compounds are gaining attention as complementary therapeutic agents. This study aimed to evaluate the anti-tumor effects of Annona muricata leaf extract on murine breast cancer 4T1 cells, used alone or in combination with cisplatin. Cisplatin induced intrinsic apoptosis through mitochondrial membrane disruption, up-regulation of the Bax gene and inhibition of the PI3K/AKT/mTOR signaling pathway. Cisplatin also promoted hypoxia by HIF1α gene expression, inflammation by TNFα and IL-6 gene expression, and induced cell cycle arrest at the sub-G1 phase by down-regulation of cyclin D1 and cyclin E1 genes. Annona muricata leaf extract triggered autophagy-mediated 4T1 cell death through mainly mTOR down-regulation and increased expression of Beclin1 and LC3 genes. It also induced cell cycle arrest at sub-G1 and S phases in a concentration- and time-dependent manner. When, combined with cisplatin, Annona muricata extract shifts the cell death pathway from intrinsic apoptosis toward autophagy by reduced caspase-3 gene expression and activity and enhanced LC3-I to LC3-II conversion. Moreover, Annona muricata extract attenuated cisplatin-induced inflammation by inhibiting TNFα and IL-6 gene expression and reinforced cell cycle arrest through suppression of the cyclin D1 gene. In conclusion, our results suggest that Annona muricata leaf extract exerts significant anti-tumor activity in breast cancer cells and may enhance cisplatin efficacy by shifting the signaling pathway from intrinsic apoptosis toward autophagy, and attenuating inflammation-related effects, supporting its potential use as a complementary therapeutic strategy.

## Linked entities

- **Genes:** BAX (BCL2 associated X, apoptosis regulator) [NCBI Gene 581], PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) [NCBI Gene 5290], AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207], MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475], HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091], TNF (tumor necrosis factor) [NCBI Gene 7124], IL6 (interleukin 6) [NCBI Gene 3569], ccnd1.S (cyclin D1 S homeolog) [NCBI Gene 379161], BECN1 (beclin 1) [NCBI Gene 8678], MAP1LC3A (microtubule associated protein 1 light chain 3 alpha) [NCBI Gene 84557], Casp3 (caspase 3) [NCBI Gene 12367]
- **Chemicals:** cisplatin (PubChem CID 5460033)
- **Diseases:** breast cancer (MONDO:0004989)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Akt1 (Akt serine/threonine kinase 1) [NCBI Gene 11651] {aka Akt, LTR-akt, PKB, PKB/Akt, PKBalpha, Rac}, Map1lc3a (microtubule-associated protein 1 light chain 3 alpha) [NCBI Gene 66734] {aka 1010001H21Rik, 4922501H04Rik, LC3, LC3a}, Casp3 (caspase 3) [NCBI Gene 12367] {aka A830040C14Rik, AC-3, CASP-3, CC3, CPP-32, CPP32}, Ccne1 (cyclin E1) [NCBI Gene 12447] {aka CycE1}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, Pik3r1 (phosphoinositide-3-kinase regulatory subunit 1) [NCBI Gene 18708] {aka PI3K, p50alpha, p55alpha, p85alpha}, Hif1a (hypoxia inducible factor 1, alpha subunit) [NCBI Gene 15251] {aka HIF-1-alpha, HIF1-alpha, HIF1alpha, MOP1, bHLHe78}, Ccnd1 (cyclin D1) [NCBI Gene 12443] {aka CycD1, Cyl-1, PRAD1, bcl-1, cD1}, Bax (BCL2-associated X protein) [NCBI Gene 12028], Becn1 (beclin 1, autophagy related) [NCBI Gene 56208] {aka Atg6}, Il6 (interleukin 6) [NCBI Gene 16193] {aka Il-6}, Mtor (mechanistic target of rapamycin kinase) [NCBI Gene 56717] {aka 2610315D21Rik, FRAP, FRAP2, Frap1, RAFT1, RAPT1}
- **Diseases:** hypoxia (MESH:D000860), inflammation (MESH:D007249), Breast Cancer (MESH:D001943), cancer (MESH:D009369)
- **Chemicals:** Cisplatin (MESH:D002945), Annona muricata Leaf Extract (-)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]

## Figures

10 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12896402/full.md

---
Source: https://tomesphere.com/paper/PMC12896402